Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
10/06/2026 12:04
BRIEF-Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare June 10 (Reuters) - Harrow Inc HROW.O:
HARROW RE-LAUNCHES VERKAZIA® (CYCLOSPORINE OPHTHALMIC EMULSION) 0.1% FOR VERNAL KERATOCONJUNCTIVITIS, ADDRESSING SIGNIFICANT UNMET NEED IN PEDIATRIC EYECARE
Source text: ID:nGNX7LYkQc
Further company coverage: HROW.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates